Serum Institute waives indemnity over AstraZeneca COVID vaccine for refugees

Published On 2021-12-24 03:30 GMT   |   Update On 2021-12-24 07:59 GMT

New Delhi: The Serum Institute of India (SII) has waived its protection from legal liabilities for any AstraZeneca-Oxford COVID-19 shots it supplies to a global programme for refugees, a spokesperson for the GAVI vaccine alliance told Reuters on Wednesday.

The news comes days after Reuters reported that tens of millions of migrants may be denied COVID-19 vaccines from the vaccine-sharing programme COVAX
because of concerns over who would be liable in the event of harmful side-effects.
Many COVID-19 vaccine manufacturers require that countries indemnify them for any adverse events suffered by individuals as a result of the vaccines. But where governments are not in control - in the case of refugees - that is not possible.
With the waiver, SII's version of the AstraZeneca-Oxford vaccine, Covishield, can now be allocated to COVAX's Humanitarian Buffer reserve of shots to be distributed by humanitarian groups, the GAVI representative said.
Advertisement
SII, the world's biggest manufacturer of vaccines which also produces a version of Novavax's COVID-19 shot, declined to comment.
AstraZeneca-Serum are currently the main suppliers of COVID-19 vaccines to COVAX, but are set to be displaced by Pfizer and BioNTech at the start of 2022.
GAVI, a public-private partnership, was set up in 2000 to promote vaccination around the world. It operates COVAX together with the
World Health Organization
to supply COVID-19 shots to poorer nations.

Serum Institute of India is an Indian biotechnology and biopharmaceuticals company headquartered in Pune, India. The company was founded by Dr. Cyrus Poonawalla in 1966.

Read also: SII, Novavax get WHO EUL for Covovax

Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News